NEW YORK (GenomeWeb News) – Exosome Diagnostics said in a regulatory filing that it has raised $6.5 million toward a targeted $8 million financing round.

In a Form D/A filed with the US Securities and Exchange Commission, the New York-based firm said the types of securities offered included debt; options, warrants, and other rights to acquire other securities; and securities to be acquired upon the exercise of options, warrants, and other rights to acquire securities.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.